Teva Pharmaceutical Industries (TEVA) Interest Coverage Ratio (2009 - 2025)
Teva Pharmaceutical Industries (TEVA) posted quarterly Interest Coverage Ratio of 0.13 for Q4 2025, up 990.93% year-on-year from 0.01 in Q4 2024, and up 990.93% on a QoQ basis from 0.01 in Q4 2024.
Teva Pharmaceutical Industries (TEVA) Interest Coverage Ratio (2009 - 2025) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Interest Coverage Ratio for 16 consecutive years, with 0.13 the latest figure, recorded in Q4 2025.
- Quarterly Interest Coverage Ratio rose 990.93% year-over-year to 0.13 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.92 (up 712.81% YoY) and the FY2025 annual result came in at 0.92, up 713.09% from the prior year.
- Interest Coverage Ratio advanced to 0.13 in Q4 2025 per TEVA's latest filing, from 0.01 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for TEVA reached as high as 0.25 in Q4 2023 and fell as low as 0.31 in Q4 2022.
- A 5-year average of 0.02 and a median of 0.03 in 2021 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio sank 1168.22% — and 2025, when it jumped 990.93%.
- Year by year, Interest Coverage Ratio stood at 0.03 in 2021, then plunged by 1168.22% to 0.31 in 2022, then surged by 182.11% to 0.25 in 2023, then tumbled by 105.72% to 0.01 in 2024, then soared by 990.93% to 0.13 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.13, 0.01, and 0.25 for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.13 |
| Dec 31, 2024 | -0.01 |
| Dec 31, 2023 | 0.25 |
| Dec 31, 2022 | -0.31 |
| Dec 31, 2021 | 0.03 |
| Dec 31, 2020 | 0.16 |
| Dec 31, 2019 | 0.21 |
| Sep 30, 2019 | -0.13 |
| Jun 30, 2019 | -0.90 |
| Mar 31, 2019 | 0.19 |
| Dec 31, 2018 | -3.50 |
| Dec 31, 2017 | -1,759.05 |
| Dec 31, 2015 | 2.31 |
| Dec 31, 2014 | 3.02 |
| Dec 31, 2013 | 4.79 |
| Dec 31, 2012 | 3.33 |
| Dec 31, 2011 | 20.51 |
| Dec 31, 2010 | 0.98 |
| Dec 31, 2009 | 0.57 |